Compare FULC & KWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | KWY |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.4M | 283.2M |
| IPO Year | 2019 | 2013 |
| Metric | FULC | KWY |
|---|---|---|
| Price | $3.77 | $9.41 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 37.6K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $134,996,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.42 |
| 52 Week Low | $2.83 | $8.41 |
| 52 Week High | $15.74 | $11.36 |
| Indicator | FULC | KWY |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 46.91 |
| Support Level | $3.75 | $8.96 |
| Resistance Level | $3.91 | $9.60 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 52.50 | 43.65 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.